Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Print  

Study Name: AeroVanc for the treatment of MRSA in people with CF
Study Type: Interventional
Intervention Category: Anti-Infective
Study Sponsor: Savara
Study Phase: 2
Recruitment Status: Recruiting
Study Drug(s): Inhaled Vancomycin
Number of Participants Being Recruited: 80
Single / Multi-Center: Multi-Center
STUDY BACKGROUND INFORMATION:
This is a Phase 2a randomized, multicenter, double-blind, placebo-controlled, parallel group study to examine the safety and effectiveness of AeroVanc in the treatment of persistent MRSA lung infection in people with CF 12 years and older. Participants will be randomized to receive Aerovanc two times a day or placebo. Specimens of blood, urine, and sputum will be taken throughout the study along with pulmonary lung function testing. The study may last up to 98 days for subjects not co-infected with P. aeruginosa and 127 days for those that are.
ELIGIBILITY
Age: >= 12 Years
FEV1: 30 - 90 Percent Predicted
P. aeruginosa status: Not applicable
B. cepacia status: Negative
Other Primary Eligibility Requirements:

Eligible subjects must be chronically infected with MRSA
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
FOR MORE INFORMATION:
Sponsor Contact Information:
Trial Specific Link on ClinicalTrials.gov: http://clinicaltrials.gov/show/NCT01746095
Clinical Research Terms Glossary: Click here
PARTICIPATING SITES:
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
FL
  • Nemours Children's Clinic - Orlando (Pediatric), Orlando, FL, 32806
    Contact Information:
        Kesser, Kenneth (Bert)
        Phone: (407) 650-7175
        Email: bkesser@nemours.org
  • Tampa General Hospital (Adult), Tampa, FL, 33606
    Contact Information:
        Roberson, Suzanne
        Phone: (813) 844-7179
        Email: sroberson@tgh.org
KY
  • University of Kentucky (Pediatric), Lexington, KY, 40536
    Contact Information:
        Watts, Tammy
        Phone: (859) 257-5087
        Email: twatt2@uky.edu
MA
  • Massachusetts General Hospital (Pediatric), Boston, MA, 02114
    Contact Information:
        Doolittle, Caitlin
        Phone: (617) 726-3719
        Email: cdoolittle1@partners.org
NC
  • University of North Carolina at Chapel Hill (Pediatric), Chapel Hill, NC, 27599
    Contact Information:
        Stephenson, Kelly
        Phone: (919) 843-7121
        Email: kelly.stephenson@unc.edu
NY
  • Children's Hospital of New York Columbia University (Pediatric), New York City, NY, 10032
    Contact Information:
        Kattan, Meyer
        Phone: (212) 305-5122
        Email: mk2833@columbia.edu
OH
  • University Hospitals Case Medical Center/Rainbow Babies and Children's Hospital (Pediatric), Cleveland, OH, 44106
    Contact Information:
        Ksenich, Roberta (Bobbi)
        Phone: (216) 844-5733
        Email: Roberta.Ksenich@UHHospitals.org
  • Nationwide Children's Hospital (Pediatric), Columbus, OH, 43205
    Contact Information:
        Johnson, Mary Terri
        Phone: (614) 722-4766
        Email: Terri.Johnson@nationwidechildrens.org
PA
  • Children's Hospital of Pittsburgh of UPMC (Pediatric), Pittsburgh, PA, 15213
    Contact Information:
        Hartigan, Elizabeth
        Phone: (412) 692-7060
        Email: elizabeth.hartigan@chp.edu
TX
  • Dell Children's Medical Center of Central Texas (Pediatric and Adult), Austin, TX, 78723
    Contact Information:
        Brazil, Isolde
        Phone: (512) 380-9200 X206
        Email: IBrazil@accapa.com
Back to top